Atherosclerotic Cardiovascular Disease Primary and Secondary Prevention in Latino Subgroups

被引:0
|
作者
Kaufmann, Jorge [1 ]
Marino, Miguel [1 ,2 ]
Lucas, Jennifer A. [1 ]
Rodriguez, Carlos J. [3 ]
Boston, Dave [4 ]
Giebultowicz, Sophia [4 ]
Heintzman, John [1 ,4 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ Portland State Univ, Sch Publ Hlth, Biostat Grp, Portland, OR USA
[3] Albert Einstein Coll Med, Dept Med Epidemiol & Populat Hlth, Bronx, NY USA
[4] OCHIN, Portland, OR USA
关键词
atherosclerotic cardiovascular disease; Latino; nativity; disparities; UNITED-STATES; RISK-FACTORS; HEALTH; SERVICES; PREVALENCE;
D O I
10.1007/s11606-024-08822-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundStudies assessing equity in the prevention of atherosclerotic cardiovascular disease (ASCVD) for Latinos living in the USA collectively yield mixed results. Latino persons are diverse in many ways that may influence cardiovascular health. The intersection of Latino nativity and ASCVD prevention is understudied.ObjectiveTo determine whether disparities in ASCVD screening, detection, and prescribing differ for US Latinos by country of birth.DesignA retrospective cohort design utilizing 2014-2020 electronic health record data from a network of 320 community health centers across 12 states. Analyses occurred October 1, 2022, to September 30, 2023.ParticipantsNon-Hispanic White and Latino adults age 20-75 years, born in Cuba, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, and the USA.ExposuresEthnicity and country of birth.Main MeasuresOutcome measures included prevalence of statin eligibility, of having insufficient data to establish eligibility, odds of having a documented statin prescription, and rates of statin prescriptions and refills. We used covariate-adjusted logistic and generalized estimating equations logistic and negative binomial regressions to generate absolute and relative measures.Key ResultsAmong 108,672 adults, 23% (n = 25,422) were statin eligible for primary or secondary prevention of ASCVD using American College of Cardiology/American Heart Association guidelines. Latinos, born in and outside the USA were more likely eligible than Non-Hispanic White patients were (US-born Latino OR = 1.55 (95% CI = 1.37-1.75); non-US-born Latino OR = 1.63 (95% CI = 1.34-1.98)). The eligibility criteria that was met differed by ethnicity and nativity. Latinos overall were less likely missing data to establish eligibility and differences were again observed by specific non-US country of origin. Among those eligible, we observed no statistical difference in statin prescribing between US-born Latinos and non-Hispanic White persons; however, disparities varied by specific non-US country of origin.ConclusionEfforts to improve Latino health in the USA will require approaches for preventing and reversing cardiovascular risk factors, and statin initiation that are Latino subgroup specific.
引用
收藏
页码:2041 / 2050
页数:10
相关论文
共 50 条
  • [41] Recommendations for the primary prevention of atherosclerotic cardiovascular disease in primary care: a systematic guideline review
    Bredehorst, Maren
    Gonzalez-Gonzalez, Ana I.
    Schuermann, Lara
    Firmansyah, Dennis
    Muth, Christiane
    Haasenritter, Joerg
    van der Wardt, Veronika
    Puzhko, Svetlana
    FRONTIERS IN MEDICINE, 2025, 11
  • [42] A Meta-analysis of the Use of Polypill for Secondary Prevention of Atherosclerotic Cardiovascular Disease
    Al-Abdouh, Ahmad
    Mhanna, Mohammed
    Jabri, Ahmad
    Ahmed, Taha
    Altibi, Ahmed M.
    Ghanem, Fares
    Alhuneafat, Laith
    Mostafa, Mostafa Reda
    Abusnina, Waiel
    Dewaswala, Nakeya
    Bhopalwala, Huzefa
    Kundu, Amartya
    Michos, Erin D.
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (02) : e193 - e195
  • [43] Trends in Statin Therapy for the Secondary Prevention in Dialysis Patients With Atherosclerotic Cardiovascular Disease
    Lee, Myunhee
    Kim, Do Young
    Hong, Yu Ah
    Park, Mahn Won
    Kim, Dae-Won
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (12) : B222 - B222
  • [44] Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease
    Leiter, Lawrence A.
    Hegele, Robert A.
    Brown, Vivien
    Bergeron, Jean
    Mackinnon, Erin S.
    Mancini, G. B. John
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (05)
  • [45] Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease
    Welsh, Robert C.
    Peterson, Eric D.
    De Caterina, Raffaele
    Bode, Christoph
    Gersh, Bernard
    Eikelboom, John W.
    AMERICAN HEART JOURNAL, 2019, 218 : 100 - 109
  • [46] Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients
    Benziger, Catherine P.
    Stebbins, Amanda
    Wruck, Lisa M.
    Effron, Mark B.
    Marquis-Gravel, Guillaume
    Farrehi, Peter M.
    Girotra, Saket
    Gupta, Kamal
    Kripalani, Sunil
    Munoz, Daniel
    Polonsky, Tamar S.
    Sharlow, Amber
    Whittle, Jeffrey
    Harrington, Robert A.
    Rothman, Russell L.
    Hernandez, Adrian F.
    Jones, W. Schuyler
    JAMA CARDIOLOGY, 2024, 9 (09) : 808 - 816
  • [47] Inequities in atherosclerotic cardiovascular disease prevention
    Gomez, Sofia E.
    Dudum, Ramzi
    Rodriguez, Fatima
    PROGRESS IN CARDIOVASCULAR DISEASES, 2024, 84 : 43 - 50
  • [48] Prevention of Atherosclerotic Cardiovascular Disease in Childhood
    Hayman, Laura L.
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (09)
  • [49] Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
    Sehrish Ali
    Natasha Dave
    Salim S. Virani
    Sankar D. Navaneethan
    Current Atherosclerosis Reports, 2019, 21
  • [50] Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
    Ali, Sehrish
    Dave, Natasha
    Virani, Salim S.
    Navaneethan, Sankar D.
    CURRENT ATHEROSCLEROSIS REPORTS, 2019, 21 (09)